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This thesis examines the pharmacoeconomic value of targeted cancer therapies (TCTs) 
applied in the Serbian context. Additionally, the differing Dutch setting served to compare 
the main inferences drawn for Serbia regarding its economic and clinical aspects. Firstly, 
burden of disease and drug utilization analyses to identify the scale of cancer burden 
and availability of TCTs in Serbia was undertaken (Part I). Subsequently, the focus was 
shifted to estimating costs and effectiveness of TCTs. Illustrative examples of metastatic 
renal cell cancer (mRCC) TCTs concerned the evaluations of two consecutive therapeutic 
lines within the Serbian and the Dutch context. Through survival analyses and one 
network meta-analysis, main methodological issues in modelling of TCTs effectiveness 
were addressed (Part II). Finally, cost minimisation models comparing the same TCTs with 
different administration routes were used to illustrate costing structures in Serbian and 
Dutch oncologic health care (Part III). 
Part I: Epidemiology of cancer and access to TCTs in Serbia
To my knowledge, the collection of long-term nation-wide estimates of age-standardised 
incidence and mortality for Serbia reflects the first publication in this specific area (Chapter 
2). Steady increase in overall cancer incidence and mortality through time was revealed 
in the observed period (1999-2009) for overall cancer and for the 4 most frequent and 
most fatal cancer sites. Although incidence of overall cancer was comparable to that 
of the European average, standardised mortality rate for overall cancer in Serbia was 
notably higher within the European ranking. Alarmingly high mortality rates were found 
for 4 cancer types: breast and cervical cancer in women and lung and colorectal cancer in 
men. Notably, trends reflect the strong aging of the Serbian population, one of the most 
important risk factors, caused by negative natural increase and negative net migration. 
Relatively high mortality to incidence ratio observed in Serbia may indicate poorer cancer 
survival than in other European countries. This could be attributed to the prevalence 
of risk factors, lack of successful organised screening programmes or delayed adoption 
of novel cancer therapeutics. Obviously, the nature of specific cancer in combination 
with potential availability of TCTs that bring survival gains determine which healthcare 
interventions have most potentials to improve current epidemiological situation. Breast 
cancer is a typical example in which survival was prolonged by successive administration 
of TCTs [1], while the effect of mammography screening on survival remains controversial 
[2-4]. Cervical cancer, however, shows how early detection through simple PAP screening 
can be a highly effective strategy in cancer prevention [5].
Notwithstanding the need for further research in identification of risk factors and 
selection of appropriate interventions, presented epidemiological data confirmed earlier 
more scattered findings that the cancer burden is substantial for Serbia [6]. As the 
proportion of elderly in Serbia is one of the highest in Europe, and it will continue to rise 
as an independent risk factor for cancer incidence and mortality, absolute numbers of 
cancer cases and deaths are even more unfavourable than age standardised rates shown 
in Chapter 3 and will continue to increase [7,8]. Obviously, in such a situation potentials 
of any TCT to improve cancer survival should be carefully considered and reflect crucial 
opportunities to enhance healthy aging.
Every TCT with market authorisation issued by the European Medical Agency (EMA) 
[9] was inspected for the reimbursement status and pharmacoeconomic assessment in 
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Serbia, the Netherlands and Scotland (Chapter 3). In total, 41 TCTs were reviewed that 
were licensed for use in 70 indications. The most of TCT indications (60) were accepted 
for reimbursement in the Netherlands and considerably less numbers with positive 
evaluations were identified for Scotland (26) and Serbia (20). Observed differences were 
based on distinctive approaches in drugs’ assessments and a crucial part of it appeared 
to be related to cost effectiveness analysis.
While in Scotland a requirement for full cost effectiveness analysis exists for all 
treatments regardless of their novelty [10], in the Netherlands two special policies may 
either grant conditional reimbursement to expensive hospital drugs inclusive TCTs or 
even exempt them from cost effectiveness analysis at initial submission [11]. Notably, in 
the Netherlands cost effectiveness analysis is required combined with real world data 
collection from the practice only 4 years after initial approval. A threshold for acceptable 
cost effectiveness is clearly defined in Scotland, but not in the Netherlands. Unlike the 
Netherlands or Scotland, Serbian health care authorities did not publish any details on 
reimbursement decisions or rationales around cost effectiveness evaluations. Only basic 
descriptions on what cost utility and budget impact analysis should be comprised of was 
provided in official documents [12].
Serbia can draw on the experiences of Scotland and the Netherlands to choose the approach 
that combines the advantageous sides of both. Clearly defining pharmacoeconomic 
criteria and publishing reasoning for each of the decisions should become standard 
procedure in Serbian submissions, including those for TCTs. Additionally, if there is a 
need for an exemption based on epidemiologic or clinical arguments, fast access policies 
with postponed submission of cost effectiveness evidence can be considered. However 
and obviously, Serbia differs markedly in many economic and clinical parameters when 
compared to Scotland and the Netherlands and this should be taken into account. 
Given the economic background of Serbia, a major part of sustainability of the drugs' 
reimbursement may be related to the availability of generic alternatives (biosimilars) for 
brand drugs. Obviously, biosimilars are yet lacking for most of the drugs within the new 
class of TCTs. Furthermore, the gross domestic product per capita (GDP/c) which in 
the end finances the health care system and thus TCTs reimbursement is 7 to 9 times 
smaller in Serbia than in Scotland or the Netherlands. One way to incorporate this core 
economic parameter is by inclusion of this GDP/c in the threshold for cost effectiveness, 
thus keeping the health care system sustainable. Notably, the World Health Organisation 
(WHO) advices to consider thresholds in the range of 1 to 3 times GDP/c [13].
Part II: Cost effectiveness of TCTs
In Chapter 4, cost effectiveness was estimated through standard area-under-the-curve 
Markov modelling for everolimus, second line treatment of mRCC in comparison to the 
best supportive care. Relying on survival data from everolimus’ pivotal randomised clinical 
trial (RCT) [14] and estimating costs for the Serbian setting, it was found that everolimus 
cannot be cost effective under common thresholds of cost effectiveness suggested by 
WHO (3 GDP/c  equalling approximately €13,500/QALY [13]). Yet, due to only a small 
incidence of mRCC the total budgetary impact of everolimus seems acceptable.
Huge uncertainty exists on the potential survival gains of everolimus. Estimates of overall 
survival (OS) from the clinical trial were affected by the allowance of cross-over for the 
patients in the control arm once they had progressed [14]. Statistical adjustment for 









not available, the only source for OS estimates remained the public submission file to the 
National Institute for Health and Care Excellence (NICE), in which the hazard multiplier 
for everolimus’ OS was calculated based on individuals’ data [16]. This hazard multiplier 
came with a wide confidence interval however, and impacts the final estimate of cost 
effectiveness more than any other parameter.
On the costs side of the incremental cost effectiveness ratio (ICER) the most dominant 
input is the cost of the drug. Therefore, under significantly different economic conditions, 
and comparable price of everolimus the mean ICER estimate at approximately €90,000/
QALY is not expected to change dramatically. Indeed, this was confirmed in one specific 
conference proceedings when a similar Markov model was used to estimate everolimus’ 
ICER in the Netherlands (€92,000/QALY) [17] and within the NICE submission for the UK 
perspective (£76,000/QALY) [16].
As discussed above, the analysis of everolimus was confronted with certain shortcomings 
deriving from data unavailability for some key parameters (Chapter 4). The proportional 
hazards’ (PH) assumption, so commonly present in survival analyses within health 
economics assessments [18,19], was necessitated by the structure of available data in 
everolimus case. To show the impact of this assumption and test an alternative approach 
of fractional polynomials (FP), progression free survival (PFS) and OS of all clinically 
effective TCTs in first line mRCC were simultaneously estimated through a network 
meta-analysis (Chapter 5).
In the network meta-analysis, 8 RCTs were included involving around 4,700 patients on 
7 treatment alternatives (interferon alpha [IFN], sunitinib, bevacizumab combined with 
IFN, pazopanib, placebo, temsirolimus combined with bevacizumab and cediranib). The 
assumption of hazards’ proportionality between all treatments coming from various RCTs 
was strongly rejected. Although theoretical grounds for PH modelling do not exist, this 
was the only approach used in network meta-analyses for mRCC assessment cited in the 
literature so far [20-26]. Comparison of FP and PH models illustrated the extent of their 
respective impact on survival estimates.
Advantages of FP modelling concerned multi-dimensional effect estimates, more 
flexible survival curves through time and allowance for treatments’ hazards to intersect. 
Applications of PH models, however, prevented intersections of treatments, relied on 
hazard rate as the only estimate of treatment effect and indirectly assumed constant 
effect through time, regardless the terminal nature of mRCC. For PFS estimates, this 
resulted in serious overestimates of survival without progression or death in the PH 
model. The most effective treatment on PFS seems to be sunitinib, followed by pazopanib 
and bevacizumab combined with IFN in both FP and PH model. The OS data were again 
affected by cross-over, yet this time there were no direct or indirect estimates to adjust 
the effect change. Using intention-to-treat data without cross-over adjustments, the FP 
and PH models differed less and their estimates were more coherent. There was no clear 
advantage for any of the treatments on OS and this is consisted with the original trials’ 
estimates [27-37].
When effectiveness estimates were put in the economic backgrounds of Serbia and the 
Netherlands, FP and PH model demonstrated huge variations in outcomes (Chapter 5). 
The combined estimates of effectiveness expressed in QALYs varied to up to 6.3 times 
(pazopanib) between FP and PH models and they were always lower with the former. 
Differences of estimated ICERs between countries generally correlated with the price 
differences of drugs and were frequently smaller than differences in ICERs estimated by 
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different models. If informal willingness to pay thresholds were set to 3 times GDP/c [13], 
none of the first line mRCC treatments would appear cost effective in Serbia (€91,000-
386,000/QALY), while only the most cost effective treatment options (pazopanib and 
sunitinib) would have some likelihood of falling below cost effectiveness threshold in the 
Netherlands (€95,000-462,000/QALY).
Part III: Cost minimisation analyses of TCTs
Recently, some TCTs became available in more than one pharmaceutical formulation. 
Generally, new formulations are expected to lower the cost of drugs’ administration 
and maintain the effectiveness of older formulations. In the examples of trastuzumab 
in Serbia and rituximab in the Netherlands, older intravenous (IV) formulations were 
compared with newer subcutaneous (SC) formulations (Chapters 6 and 7). Since new 
SC formulations have shown non-inferior efficacy in comparison to the standard IV 
drugs [38-41], cost minimisation models were considered sufficient for the economic 
evaluation of proposed TCT formulations. Within the cost minimisation framework it 
was also possible to analyse differences in disease management and resource use costs 
between Serbia and the Netherlands. 
Cost minimisation models were differently designed in the Serbian and the Dutch study. 
Notably, the Dutch study followed the clinical trial design and collected measurements of 
time and costs spent in practice for administration of IV and SC rituximab in diffuse large 
B-cell lymphoma (DLBCL) during the trial. The Serbian study was based on the estimates 
of time and costs provided by clinicians per each of the steps in the administration 
algorithm, for IV and SC trastuzumab in early and metastatic breast cancer (BC). Both 
studies confirmed that new SC formulations could be cost saving strategies which when 
transferred to the whole DLBCL and BC bring reasonable savings (Chapters 6 and 7). 
Important parts of the savings came from differences in drug costs (SC versus IV) 
due to the different dosing regimens of two formulations in both health care systems. 
Yet, substantial discrepancy exists in the scale of the savings other than drug costs. 
Considerable differences between Serbia and the Netherlands were noted. While savings 
in time spent in facilities were impossible to be expressed monetary in Serbia, these 
savings contribute the most to the total costs’ difference observed in the Netherlands 
(Chapters 6 and 7). Additionally and in the absence of cost price estimates, labour wages 
of a nurse or an oncologist could not be expressed dependently on the number of offered 
services in Serbia, and therefore these expenses were neglected in the presented cost 
minimisation study (Chapter 6). Although underestimated in this way, savings in time 
of medical staff and facilities established through CMA in Serbia can have huge impact 
on BC clinical practice. This illustrates an urgent need for better costing data in Serbia, 
potential along the lines of the specified Dutch Framework for Costing [42].
Policy recommendations
The final goal of this thesis was to draw inferences on potential TCTs’ cost effectiveness 
in Serbia and provide recommendations for conduct of rational reimbursement policy 
towards this group of drugs relying on the Western European/Dutch experiences. From 
the presented cost effectiveness estimates of selected mRCC TCTs, it can be concluded 
that none of the examined drugs appears cost effective under the common threshold. 









between the countries and once the effectiveness is properly estimated, the main driver 
of cost effectiveness likely remains the cost of the drugs. Based on the existing price 
parities among countries for most of TCTs, relatively good transferability of the estimated 
ICERs can be assumed. Under this assumption most of the TCTs’ ICERs reviewed in this 
thesis for the Netherlands or Scotland will not be found cost effective in Serbia. Main 
discrepancy appears in a low economic capacity of Serbia to finance the drugs estimated 
at the upper limits of cost effectiveness thresholds in some of the most developed 
countries. 
More broadly, under present TCTs’ pricing any mid-income country (€1,000 – €11,000 
of GDP/c [43]) would be faced with similar dilemma on their reimbursement. Although 
it is clear that most TCTs will hardly comply with the standard cost effectiveness merits, 
sensitive question arises on whether they should actually be put in these standard 
merits [44,45]. Some of the most influential institutions renowned for rigorous health 
economic assessment such as the British NICE, or the Scottish SMC apply specific end-
of-life treatment guidelines or decision modifiers in case of TCTs [46,47]. These allow 
reimbursement of a TCT despite exceeding regularly determined cost effectiveness 
thresholds if a TCT: (i) does not have therapeutic alternative; (ii) prolongs life for at least 
3 months; (iii) constitutes relatively small budgetary impact. Furthermore, presented 
policies in the Netherlands (Chapter 3) are created to enable fast access for clinically 
proven expensive hospital drugs. Economic evaluation in such situations is necessitated 
4 years after initial approval and it should include collected real world data on treatment’s 
effectiveness [48]. 
It was out of the scope of this thesis to determine and define the most appropriate policy 
on TCTs reimbursement. It, however, identified Serbia as a country with substantial and 
rising burden of cancer, which emphasised importance for proper and, perhaps, specific 
TCT evaluation. Neither of TCT policy models described here (Dutch or Scottish) did 
exclude pharmacoeconomic assessment from the reimbursement process. Moreover, it 
is the economic evaluation that proved crucial for the reimbursement of TCTs. Serbia 
should, therefore, clearly specify reimbursement criteria and within them elucidate 
details of the TCTs pharmacoeconomic assessment.
Modelling the effectiveness of TCTs is a demanding task. This thesis emphasises the 
importance of accounting for all underlying assumptions in TCTs’ survival analysis. With 
the yet rarely practiced approach of FP, it proves feasible and advantageous to model 
networks of evidence on survival analysis. Within the field of novel TCTs which triggers 
debates on proper use of cost effectiveness, methodological issues should be tackled 
with caution and with help of specific guidelines. This can be particularly important 
for countries that recently implemented cost effectiveness policy, such as Serbia and 
experiences from the Western European countries – such as the Netherlands – can help 
here [49]. 
Future perspectives
Results of this thesis opened the perspectives for further research. Although 
fundamental epidemiologic and pharmacoepidemiologic data for Serbia were collected in 
the field of cancer and TCTs to facilitate presented analyses, some basic data for future 
pharmacoeconomic assessments are still missing. These include country specific utilities 
per each of the cancers and per the disease phases and establishment of willingness-to-
pay thresholds and would require nation-wide surveys. From the clinical perspective it 
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would be interesting to confront findings of this thesis on TCTs cost effectiveness and 
potential outcomes on preventive strategies’ cost effectiveness in Serbian setting. Only 
balanced utilisation of curative and preventive methods relying on rational cost utility 
assessment can lead to sustainable reduction of cancer burden in Serbia. 
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